A Texas-Illi­nois can­cer biotech search­es for more Se­ries B cap­i­tal two years af­ter ex­ten­sion

A Texas biotech try­ing to treat var­i­ous can­cers, in­clud­ing re­frac­to­ry ones for pe­di­atric pa­tients, is on a wind­ing fi­nanc­ing jour­ney.

About 12 months af­ter dis­clos­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER